NCT06427941
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- NCT06427941 ↗
- Recruiting
- BeOne Medicines
- Focused
We haven't built an HCP commentary report on NCT06427941 (BGB-B2033; BGB-B2033 plus tislelizumab; BGB-B2033 plus tislelizumab plus bevacizumab in advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06427941 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer; Extragonadal Yolk Sac Tumors; Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
- Interventions
- BGB-B2033; Tislelizumab; Bevacizumab
- Arms
- Part A (Monotherapy Dose Escalation and Safety Expansion) · Experimental
- Part B (Doublet Run-in) · Experimental
- Part B (Triplet Dose Escalation) · Experimental
- Part B (Triplet and Doublet Safety Expansion) · Experimental
- Part C (Asia Monotherapy Dose Expansion in HCC) · Experimental
- Part D (US Monotherapy Dose Expansion in HCC) · Experimental
- Part E (Monotherapy Dose Expansion in HCC) · Experimental
- Enrollment
- 630 (estimated)
- Primary outcomes
- Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033
- Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033
- Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
- Sponsor
- BeOne Medicines
- Start
- Jul 23, 2024
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06427941 · updated Sep 16, 2026